New Weight-Loss Drug's body fat impact revealed in early trial
NCT ID NCT06824051
Summary
This early-stage study tested how a new drug called orforglipron changes body fat, especially deep belly fat, in adults with obesity or overweight who do not have diabetes. It compared the drug's effects to a placebo (inactive substance) in 120 participants over about 8 months. The main goal was to understand how the drug works in the body to potentially help control weight.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Axis
Dilworth, Minnesota, 56529, United States
-
Clinical Pharmacology of Miami
Miami, Florida, 33172, United States
-
Endeavor Clinical Trials
San Antonio, Texas, 78240, United States
-
Ohio Clinical Trials
Columbus, Ohio, 43212, United States
Conditions
Explore the condition pages connected to this study.